Objective: To test efficacy of 8-session, 1:1 treatment, anger self-management training (ASMT), for chronic moderate to severe traumatic brain injury (TBI). Setting: Three US outpatient treatment facilities. Participants: Ninety people with TBI and elevated self-reported anger; 76 significant others (SOs) provided collateral data. Design: Multicenter randomized controlled trial with 2:1 randomization to ASMT or structurally equivalent comparison treatment, personal readjustment and education (PRE). Primary outcome assessment 1 week posttreatment; 8-week followup. Primary Outcome: Response to treatment defined as 1 or more standard deviation change in self-reported anger. Secondary Outcomes: SO-rated anger, emotional and behavioral status, satisfaction with life, timing of treatment response, participant and SO-rated global change, and treatment satisfaction. Main Measures: StateTrait Anger Expression Inventory-Revised Trait Anger (TA) and Anger Expression-Out (AX-O) subscales; Brief Anger-Aggression Questionnaire (BAAQ); Likert-type ratings of treatment satisfaction, global changes in anger and well-being. Results: After treatment, ASMT response rate (68%) exceeded that of PRE (47%) on TA but not AX-O or BAAQ; this finding persisted at 8-week follow-up. No significant between-group differences in SO-reported response rates, emotional/behavioral status, or life satisfaction. ASMT participants were more satisfied with treatment and rated global change in anger as significantly better; SO ratings of global change in both anger and well-being were superior for ASMT. Conclusion: ASMT was efficacious and persistent for some aspects of problematic anger. More research is needed to determine optimal dose and essential ingredients of behavioral treatment for anger after TBI. MSW, Donald Gerber, PsyD, Gillian Murray, MSW, Claire McGrath, PhD, Josh Dyer, PhD, and Kevin Alschuler, PhD, provided Treatment approaches have included pharmacologic agents, among which methylphenidate 10 and amantadine hydrochloride 11 may be the most promising for people with chronic TBI and irritability; β-blockers can reduce overt aggression.
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and behavior, 8 and cognitive deficits affecting communication and inference in social situations 9 may all play a role. In addition, limitations in financial and personal independence and loss of meaningful activity can compound frustration.
Treatment approaches have included pharmacologic agents, among which methylphenidate 10 and amantadine hydrochloride 11 may be the most promising for people with chronic TBI and irritability; β-blockers can reduce overt aggression. 12 However, there is still insufficient evidence to support a standard pharmacologic approach to anger after TBI, and several commonly used agents may impede cognitive recovery. 13 Behavioral approaches include operant conditioning, which have been successful in tightly controlled (eg, residential) environments.
14 Psychoeducational approaches have also been attempted. For example, a small randomized controlled trial 15 suggested that people with acquired brain injury (TBI, stroke) could learn principles of anger management that are effective in the general population. 16, 17 Eight people receiving this oneon-one treatment had greater reduction in self-reported outward expression of anger compared with 8 who were wait-listed. Several uncontrolled studies 18, 19 have noted positive findings using similar content in a group format.
Based in part on these encouraging findings, we conducted a multicenter randomized controlled trial to test the efficacy of a manualized, one-on-one, psychoeducational treatment protocol called anger self-management training (ASMT). 20 Feasibility and initial evidence of efficacy were examined in a pilot trial, which suggested that the protocol was suitable for people with cognitive limitations due to TBI. 21 The ASMT treatment is based on the idea that, regardless of the individual contributions of premorbid, organic, and secondary causes, there is a "final common pathway" for the experience and expression of anger linked to 2 deficits in executive function that affect many survivors of TBI: (1) impaired self-awareness, which affects behavioral problems more than cognitive or physical deficits 22, 23 ; and (2) limitations in problem solving, particularly in social spheres. 24 Although many people with anger/irritability because of TBI do apprehend the problem in a general way, they may underestimate its magnitude and consequences, blame others, and produce stereotyped angry reactions to anything perceived as a threat. Self-monitoring has been successfully taught even to people with severe cognitive impairment after TBI, 25, 26 and teaching the steps of problem solving has been recommended for executive dysfunction due to TBI on the basis of a systematic review of the literature. 27 Consequently, we designed the ASMT around 2 types of "active ingredients:" methods of improving self-monitoring and self-awareness of anger, and problem-solving methods that would provide a more flexible repertoire of responses to challenging situations.
We encountered difficult choices in selecting a control or comparison condition for the ASMT trial. A usual care comparison was not feasible because there is no standard treatment for anger and irritability after TBI, and many patients in the chronic phase receive no treatment at all for emotional or behavioral issues. 28 We decided against a wait-list control because of the anticipated length of the trial, as well as evidence that wait-listing can bias outcomes in favor of experimental treatments. 29 Yet, we deemed it important to control for nonspecific but beneficial effects of a one-on-one treatment that included an opportunity to ventilate feelings as well as time, attention, and education given by an empathetic professional. We therefore developed a comparison treatment called personal readjustment and education (PRE), which was structurally similar to ASMT in the format, intensity, degree of manualization, provision of outside assignments, and other features described later.
The primary hypothesis was that there would be greater improvement in self-reported anger from preto posttreatment in the ASMT condition than in the PRE condition. Specifically, 1. We predicted that there would be at least 20% greater response rate (defined later) in the ASMT than in the PRE condition, as well as significantly greater decrease in self-reported anger in the ASMT condition. 2. We also examined the trajectory of treatment response, with the expectation that at least half of the participants who responded to ASMT treatment would do so by the fourth session, and that this rate would be at least 10% higher than that in the PRE condition. 3. We hypothesized that the maintenance in ASMT response rate at 2-month follow-up would exceed that of the maintenance of gains in the PRE condition by at least 10%. 4. Finally, we examined whether the 2 conditions would have differential effects on reports of participant anger given by relatives or friends (significant others, or SOs), satisfaction with treatment and perception of global change, and secondary outcomes including emotional distress, self-and SO-rated behavioral dysfunction, and satisfaction with life.
Anger Self-management Training for Chronic Moderate to Severe TBI 321 problematic anger. After a baseline assessment that included primary and secondary outcome measures and other instruments to characterize the sample, participants were randomized in a 2:1 ratio to ASMT or PRE, respectively, in blocks of 3 within each center. This ratio was selected to provide more data for examining predictors of clinical response and other characteristics of the treatment arm of primary interest. Assessment was done at baseline (T1), after the fourth treatment session (T2), 1 week after the eighth or last treatment session (T3), and 8 weeks after the T3 evaluation (T4) by examiners masked to treatment condition. Primary outcome was measured at T3.
Participants
Details of inclusion and exclusion criteria are reported elsewhere 20 and in the Supplemental Digital Content (SDC). In brief, we recruited persons who were known to have TBI and some indication of problematic anger via self-, SO-, or clinician report. Participants had to be aged 18 to 65 years, 6 months or more postinjury, and reporting anger that was new, or worse, since the TBI. They also had to score 1 standard deviation (SD) or more above the mean for age and gender on the Trait Anger (TA) or Anger Expression-Out (AX-O) subscales of the State-Trait Anger Expression Inventory-2 (STAXI-2), 30 or a score of 9 or more on the Brief Anger-Aggression Questionnaire (BAAQ). 31 Participants were excluded for major mental illness and involvement in one-on-one psychotherapy.
Significant others
All participants were encouraged to nominate an SO to participate in the trial; however, an SO was not necessary for inclusion. SOs were asked to contribute data concerning the participant at each evaluation (T1 through T4). SOs who were willing and able also participated in 3 of the 8 sessions in the ASMT or PRE treatment.
Measures
TBI-related variables included time postinjury, mechanism of injury, and severity, as judged by retrospective estimation of posttraumatic amnesia duration. This was ascertained using a structured interview that has been used in other studies of chronic TBI, with the retrospective estimate found to correlate reasonably well with posttraumatic amnesia measured prospectively. 32, 33 All participants' TBI severity was confirmed for study inclusion using prospective medical records; however, not all prospective severity indices (eg, Glasgow Coma Scale) were available for all participants. Neuropsychological status was measured at baseline (T1) using the Wechsler Abbreviated Scale of Intelligence (Vocabulary and Matrix Reasoning subtests) 34 ; the Rey Auditory Verbal Learning Test 35 sum of trials 1 to 5; the Trail Making Test, Part B T-score 36 ; and the error score from the Brixton Spatial Anticipation Test. 37 Overall functional status was measured with the Glasgow Outcome ScaleExtended. 38 The primary outcome, treatment response from T1 to T3, was defined as 1 or more SD change in the direction of improvement on any of the 3 self-report scales used to measure anger at baseline: TA and AX-O from the STAXI-2, and the BAAQ. The TA and AX-O scales are standardized to have the SD of 10, 30 and the SD of the BAAQ was determined through previous research. 31 These 3 scales were chosen because the pilot study of the ASMT suggested variability as to which of them would capture treatment response for individual participants, and the change of 1 SD roughly corresponded to selfand SO-reported change in functional status because of reduction in anger. 21 The STAXI-2 is worded at the sixth-grade level and has favorable psychometric properties, furnishes age-and gender-corrected T-scores, and is widely used in mainstream anger treatment trials. The 6-item BAAQ is sensitive to more extreme behavioral manifestations of anger, including passive aggression. 31 Secondary outcomes were measured by changes from T1 to T3 and included participant anger measured on all 3 scales from the point of view of the SO; emotional status as measured by the Global Severity Index of the Brief Symptom Inventory, 39 the extent of frontal/executive dysfunction as measured by self-and SO-report on the Frontal Systems Behavior Scale (FrSBe) 40 total T-score, and satisfaction with life using the Diener Satisfaction With Life Scale. 41 Concurrent treatments, including psychoactive medications and doses, were measured at each assessment using a structured interview developed for the study.
To assess the credibility of the PRE condition, both participants and SOs (if participating in treatment) were contacted by study coordinators after the first treatment session of either condition and asked to rate 3 items on a Likert-type scale from 1 (not at all) to 5 (very much) as to their confidence that the treatment would help the participant; how relevant the treatment seemed for his or her problems; and how much they expected the therapist to help. Responses were added to create expectancy scores ranging from 3 to 15.
Satisfaction with treatment and global assessment of treatment effectiveness was assessed after the eighth session (or the last one attended, if participants dropped out early). For satisfaction with treatment, coordinators asked 5 Likert-type questions of the participant and SO using the same response scale as earlier, regarding the degree to which the treatment had helped the participant; how relevant the treatment was for his/her problems; the extent to which the therapist had helped him/her; how 322 JOURNAL OF HEAD TRAUMA REHABILITATION/SEPTEMBER-OCTOBER 2017 well the treatment met his/her personal needs; and the extent to which the treatment would be recommended to others. Scores were summed to create satisfaction scores ranging from 5 to 25. Finally, participants and SOs were asked to rate on a scale from 1 (very much better) to 7 (very much worse) "how (participant's) anger is now, compared with how it was before you began the study," and "how this treatment has affected (participant's) general well-being, compared to before you began the study." The question about well-being was included to allow for assessment of global nonspecific effects of the PRE condition.
Procedures
Study procedures were approved and overseen by institutional review boards at the participating institutions. All participants and SOs provided informed consent. After consent and T1 assessment, participants were randomized using a computer-generated table provided by the study's Data Coordinating Center, and assigned to the therapist corresponding to their treatment condition. The randomization table revealed only the allocation of the current participant and was used only by the site study coordinators, the only personnel aside from the therapists who were unmasked to treatment. The T2 (interim) assessment included all 3 anger measures administered to both participant and SO, as well as the assessment of concurrent medications. The T3 (posttreatment) and T4 (8-week follow-up) assessments included all the anger measures plus the measures required to test the secondary hypotheses. T2, T3, and T4 assessments were conducted by phone (or in person if preferred by the participant/SO) by research assistants who were masked to treatment condition (see SDC for details on maintenance of masking). Data collectors completed a form at each assessment indicating whether they had been inadvertently unmasked. All assessment instruments were double-scored (ie, scored independently by the data collector and another person at each site) to minimize errors before data entry.
Interventions
Each of the treatment conditions was designed to be completed in 8 weekly sessions of up to 90 minutes each. Participants who deviated in the extreme from this schedule could be terminated from treatment, on the rationale that participants who received the therapy at widely spaced or erratic intervals would not be expected to receive the same benefit as those who participated at the planned therapy intensity (see SDC for details of termination protocol). If an SO was involved in treatment, that person was invited to participate in portions of sessions 1, 4, and 8. The core philosophy, session content, and other aspects of the ASMT and PRE conditions are detailed in Table 1 . In brief, the ASMT protocol emphasizes the teaching of behavioral skills (self-monitoring, problem-solving) in addition to focused education about anger and its links to TBI. The PRE protocol provides education about the effects of TBI on personal characteristics, relationships, and community roles. It proscribes advice or guidance from the therapist in favor of empathetic listening, reflection, and encouragement to pursue one's own posttraumatic readjustment. Both conditions are structured so as to minimize the impact of the cognitive deficits associated with TBI. Additional information about the treatment conditions has been published previously. 20, 21 All treatment sessions in the current trial were audio recorded. We monitored throughout the trial for adverse events (AE) and serious adverse events (SAE) with the assistance of a safety monitor, a psychologist with expertise in the topic who examined unmasked AE and SAE reports to ensure adequate documentation and to alert us to any disproportionate counts in the 2 treatment arms. Further details of risk monitoring are provided in the SDC accompanying this article.
Study therapists were required to have at least 1 year of experience in providing counseling to people with TBI, and a Masters or Doctorate in a relevant clinical discipline. Each site provided 2 therapists, who were randomly assigned to either ASMT or PRE to minimize biases associated with treatment preferences. Therapists in the 2 conditions received separately delivered but equivalent amounts of training, supervision, and feedback on the basis of fidelity assessment (see the SDC accompanying this article).
Data analysis
We compared the characteristics of the 2 treatment groups using χ 2 or Fisher's exact test (depending on cell sizes) for categorical variables, and Mann-Whitney tests for ordinal or continuous variables. Analyses of primary hypotheses concerning treatment effects were conducted under intent-to-treat assumptions in which participants with missing outcome data were considered nonresponders. The rationale for selecting the 20% cutoff as a meaningful between-group difference in response rate is presented in the SDC accompanying this article.
We also conducted analyses using only participants who supplied outcome data. We compared response rates overall (primary outcome) and on individual measures of self-reported anger using χ 2 tests. We used a Fisher's exact test to compare the proportions of those responding at T2 in each treatment arm who were classified as responders at T3. The time by treatment interaction in linear mixed effects models, with time considered as categorical for both evaluation of 3 or 4 time points Training and practice in active listening, a technique to enhance understanding of the viewpoints of others and to avoid nonconstructive argument.
Outer circle I: discussion of meaning of "community" and how P sees his/her belongingness, participation, and contribution as having changed, and not changed, since TBI. Discussion of changes in roles, if any. Session 7
Self-assessment and consolidation of skills: P completes self-assessment of progress, evaluates own strengths and weaknesses related to program content, and reviews/practices techniques felt to be most in need of shoring up.
Outer circle II: P completes self-assessment of progress to date; T prompts discussion of activities out in the community and how these may have been affected by TBI, as well as self-assessment of most fulfilling activities. SO participates in portions of sessions 1, 4, and 8, and provides brief telephone feedback privately to the T between sessions 6 and 7, to complete a brief progress assessment parallel to the P's self-assessment.
Proscribed elements
Topics or concerns not covered in treatment manual; T reminds P that program is focused on anger-related issues and encourages P to seek other help for different issues.
Directive counseling or giving of advice; T must not suggest specific strategies but may encourage P to create and try things on his/her own using his/her own best ways to adjust.
Abbreviations: ASMT, anger self-management training; P, participant; PRE, personal readjustment and education; SO, significant other; T, therapist; TBI, traumatic brain injury. a Reprinted from Hart et al. 20 Used with permission.
and linear for the 3 time points T1, T2, and T3, was used for overall summarization of the treatment effect on the scores from the 3 or 4 assessments. In addition to effects of time, treatment group, and their interaction, the models were adjusted for site. Alpha was set at .05 both for the a priori hypotheses and also for secondary analyses, which we considered exploratory in nature. Effect sizes at T3 and T4 were calculated using a metric recommended for clinical trials that use a binary outcome, the number needed-to-treat (NNT). 42 The NNT, the ideal value of which is 1, represents the number of patients who would need to be treated in one condition (in this case, ASMT) to gain 1 more patient responding to the treatment compared with the outcome if the same numbers were treated in the other condition (PRE). It is calculated as the inverse of the difference between response rates, that is, 1/([ASMT response rate] − [PRE response rate]).
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RESULTS
The flow of participants is displayed in Figure 1 . More than 80% of participants in each treatment arm completed all 8 therapy sessions. Treatment conditions were well balanced on demographic, injury, and neuropsychological variables (see Table 2 ). The typical participant was of average intelligence but worse than average in new learning 44 and executive function both by objective measures (Trails B, Brixton) and self-report (FrSBe). Selfreported emotional distress was, on average, elevated to the clinically significant range. 39 There were no significant between-group differences in the proportions of SOs enrolled for participation in treatment and/or data collection. Before randomization, 15 (50%) PRE SOs and 38 (63%) ASMT SOs agreed to attend treatment sessions and contribute data. Nine (30%) PRE participants and 14 (23%) ASMT participants lacked an SO to fulfill either role at the time of randomization.
Primary and secondary outcomes
In the analyses described next, there were no significant differences accountable to treatment site. The treatment response data are shown in Table 3 . At the primary outcome assessment (T3), the difference in the proportions of responders measured by any of the 3 self-report scales was smaller than hypothesized and not statistically significant, whether cases with missing data at T3 were considered to be nonresponders (protocol-specified primary analysis) or whether they were omitted from the analysis. However, the difference in response rates for the STAXI-2 TA scale alone was approximately the size hypothesized in favor of the ASMT condition, and was statistically significant. Differences in response rate as reported by the SOs were smaller, with none approaching significance. Interestingly, at T4 (8 weeks posttreatment), the self-reported overall response rates had improved in the ASMT condition and deteriorated slightly in the PRE condition. This pattern yielded an overall response difference in favor of ASMT that was about as large as that hypothesized for the primary outcome measured at T3, and which almost reached the nominal level of statistical significance. Regarding clinical effect sizes, at T3 the NNT to achieve a response with ASMT compared with PRE was 11.9; at T4, NNT was only 5.0. There was no significant difference in response rate in either condition, at either T3 or T4, between participants who took psychoactive medications (54% in PRE condition, 55% in ASMT condition) versus those who did not (data not shown).
The proportions of those who responded to treatment at T3 who had shown a response by the T2 evaluation are shown in Table S-1 (Supplemental Digital Content, available at: http://links.lww.com/JHTR/A203). In both treatment conditions, over half of those who responded at T3 also showed response at T2, as hypothesized. However, although the difference in this rate favored ASMT by more than 10%, which was also hypothesized, the between-group difference did not reach statistical significance. Table 4 displays the adjusted mean anger scores and the results of the mixed effects model analyses of changes in anger over time. It may be seen that mean values on the anger measures were more than 1 SD above normative values at baseline (T1) and were almost identical in the 2 conditions. The analyses of change did not reveal any differential treatment effect on any of the primary measures, although there was a trend toward greater decrease on the STAXI-2 TA scale in the ASMT condition during treatment (T1 through T3), when the effect of time was considered to be linear. Linear mixed effects models for the secondary outcome measures measured at T1, T3, and T4 revealed no significant time by treatment interactions (see Table S anger for those in the ASMT condition compared with the PRE condition. SOs indicated more expectancy of change in treatment for the ASMT condition, and also rated both anger change and change in well-being significantly better for participants in the ASMT condition compared with those in PRE.
Other findings, including the results of fidelity assessment, the success of allocation masking, and the incidence of AEs and SAEs, are presented in the SDC accompanying this article.
DISCUSSION
In this investigation we compared ASMT, an anger self-management protocol developed specifically for chronic, moderate/severe TBI, with a structurally equivalent treatment (PRE). The PRE condition was deliberately lacking in the ASMT's active ingredients (ie, training in self-awareness of anger and problem-solving methods for anger-provoking situations), but included nonspecific ingredients such as education, therapist empathy and attention, and the opportunity to ventilate feelings. The comparison was thus a stringent one, as nonspecific ingredients are known to exert powerful influences on emotional and behavioral status, 45 and their effects are considered by some to be inseparable from those of theoretically motivated elements in many psychoeducational treatments. 29 We therefore expected treatment response in both conditions, but hypothesized a greater response in ASMT compared with PRE. The primary hypothesis was not supported, in that we did not observe a superior response rate within a week of treatment cessation on any of 3 measures of selfreported anger that had shown responsiveness in a pilot trial. 21 However, there was a significantly greater posttreatment response rate to ASMT compared with PRE for one measure, the Trait Anger scale from the STAXI-2. These findings underscore the differences among these measures and may provide clues as to the strongest effects of the intervention approaches tested in this trial. Trait anger is described by the STAXI-2 developers as the tendency to perceive a range of situations as
TABLE 3
Response rates overall and for each anger measure included in the primary outcome by self-and SO report . annoying, frustrating, or unjust and to respond with anger, whereas outward expression of anger refers to specific behaviors such as nasty or sarcastic remarks, arguing, slamming doors, and other acts of verbal or physical aggression. 30 It is plausible that the psychoeducational emphasis of the ASMT protocol, especially in the first sessions, which focus on greater awareness of anger and the "reasons" for one's anger in a range of situations, could invoke a greater change in the interpretation of situations that can trigger anger, versus the idiosyncratic behaviors used to express it.
The examination of treatment response 8 weeks after the end of treatment revealed a trend for further differentiation of the effects of the 2 treatments. There were more treatment responders at 8 weeks compared with shortly after treatment in the ASMT condition, whereas the opposite pattern was true for the PRE condition. Interestingly, for ASMT participants, the response rate had increased for the Anger Expression-Out scale between 1 and 8 weeks posttreatment. Although this is speculative, it may be the case that outward expressions of anger are akin to habits, which take more time and reflection to change compared with the inward reactions of annoyance or irritation.
The interim treatment response (T2) was included in the trial because the 2 main "active ingredients," selfawareness and problem-solving, are addressed in that order in roughly the first and second halves of the ASMT manual (see Table 1 ), and there was anecdotal evidence from the pilot investigation 21 that significant changes were noted by participants and SOs around the fourth session of ASMT. In this larger sample, almost threequarters of those who showed treatment response to ASMT did so at the interim assessment. This finding suggests that a briefer treatment sequence, which would be more practical from a clinical standpoint, might be beneficial for a substantial number of persons with anger related to TBI. However, further study would be needed to determine whether a truncated program would indeed be efficacious and also persist beyond treatment, as observed here in the T4 assessment.
Despite the relatively small number of SOs who provided satisfaction and global change ratings following treatment, the findings in this area were encouraging. The ASMT SOs rated participants as having significantly more improved anger and emotional well-being overall, compared with PRE SOs (see Table 5 ). Indeed, 70% of ASMT SOs rated participant anger as "much" or "very much" better after treatment, compared with only 25% of PRE SOs. For their part, the ASMT participants were significantly more satisfied with treatment and rated their anger as significantly more improved compared with their PRE counterparts, although self-ratings of improved well-being were similar in the 2 conditions. The SO ratings noted earlier stand in contrast to the degree of change noted on the standardized measures of participant anger administered soon after treatment and 8 weeks later. At neither interval did the SO reports show any superiority for ASMT over PRE. Perhaps the discrepancy may be due to the fact that the global rating asked for an immediate comparison to pretreatment (ie, perceived change), whereas the standardized scales require a judgment as to absolute levels of anger at a given point in time. The negative findings on the formal SO assessments of participant anger are reminiscent of those of Hammond and colleagues. 11 They found that amantadine resulted in somewhat better self-ratings of aggression and irritability compared with placebo, but there was equivalent improvement in the 2 conditions according to observers (SOs). We agree with those researchers that more work should be devoted to disentangling specific from nonspecific effects of interventions tested in clinical trials. For behavioral trials such as the one reported here, this will be especially challenging because nonspecific elements such as therapist empathy and the ability to engage the patient in treatment are undoubtedly partly responsible for the uptake of specific "active ingredients." 46 Although effects of the ASMT were not as strong as expected against a structurally equivalent control, the findings of this study are encouraging in several respects. The fact that more than 80% of participants completed all 8 sessions is supportive of the feasibility of the program. The concepts and techniques taught in the ASMT appeared to be understandable and usable by participants with chronic anger and irritability and significant cognitive impairments. However, it should be kept in mind that all participants resided in the community and were excluded for serious limitations in communication. Thus, it cannot be assumed that the concepts and techniques taught in the ASMT would be accessible to those with very severe cognitive or communication deficits. Nor would our results necessarily generalize to people with TBI who deny anger problems that are apparent to others, as all participants had to self-report problems with anger in order to enter the trial. In further investigations we will examine the neuropsychological variables and other factors that predict response to this treatment approach, and use qualitative information obtained at follow-up to assess the most durable features of the ASMT program. Future research should continue to examine the characteristics of the various scales that measure anger and aggression, particularly with respect to persons with TBI-related anger, and should determine the optimal combination of treatment modalities to prevent and ameliorate this important clinical problem.
